Observational studyAIDS (London, England)2025
Associations between HIV serostatus and coronary artery plaque volume progression.
Observational study in AIDS (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectiveMen with HIV have more coronary atherosclerosis than men without HIV. We examined whether plaque progression differed based on HIV serostatus.
designWe examined plaque progression over a median of 4.5 years [interquartile range (IQR) 3.9-4.9] among 548 men with ( n = 313) or without ( n = 235) HIV from the Multicenter AIDS Cohort Study using coronary CT angiography.
methodsChange in coronary plaque volume was calculated for total, calcified, noncalcified, and low attenuation plaque and categorized by tertile. Multinomial logistic regression models estimated the association between HIV and coronary plaque progression.
resultsThe median age was 53 years and 30% were Black. Total plaque volume regressed among 2 and 20% remained without plaque, and 78% had progression with a median progression of 34 mm 3 (IQR 3-106). Compared to men without HIV, men with HIV had a statistically significant 1.99 higher odds of calcified plaque progression [95% confidence interval (CI) 1.16-3.44, P = 0.01] and elevated odds for progression in total plaque [odds ratio (OR) 1.62, 95% CI: 0.94-2.77, P = 0.08] and noncalcified plaque volume (OR 1.64, 95% CI 0.97-2.79, P = 0.07], although the latter findings did not meet the cutpoint for statistical significance. The progression of low attenuation plaque did not significantly differ by HIV serostatus (OR 1.34, 95% CI: 0.88-2.05, P = 0.18). HIV was significantly associated with the progression of total, calcified, and noncalcified plaque among non-Black participants, but not Black participants.
conclusionThese results suggest that men with HIV may have greater plaque progression, which may contribute to the observed higher incidence of coronary heart disease among men with HIV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.